Table 2.
Patient | Total Arm Dose | |||||
---|---|---|---|---|---|---|
Week 0 (1st Injection) (N = 31) | Week 12 (2nd Injection) (N = 29) | Week 24 (3rd Injection) (N = 23) | ||||
Motor Dominant | Non-Motor Dominant | Motor Dominant | Non-Motor Dominant | Motor Dominant | Non-Motor Dominant | |
1 | 160 | 100 | 225 | 160 | 270 | 205 |
2 | 190 | 160 | 190 | 225 | 190 | 235 |
3 | 190 | 120 | 180 | 110 | No injection (a) | |
4 | 175 | 215 | 170 | 150 | No injection (c) | |
5 | 100 | 119 | 105 | 140 | No injection (c) | |
6 | 270 | 300 | 195 | 215 | 185 | 205 |
7 | 160 | 105 | No injection (a) | |||
8 | 90 | 60 | 155 | 105 | 150 | 70 |
9 | 60 | 60 | 60 | 60 | 60 | 60 |
10 | 180 | 260 | 180 | 300 | 180 | 300 |
11 | 100 | 110 | 100 | 110 | 100 | 110 |
12 | 100 | 100 | 130 | 135 | 130 | 135 |
13 | 70 | 110 | No injection (b) | |||
14 | 200 | 125 | 200 | 125 | 185 | 125 |
15 | 195 | 155 | 195 | 155 | 195 | 155 |
16 | 100 | 55 | 100 | 55 | 100 | 55 |
17 | 140 | 110 | 195 | 110 | 205 | 140 |
18 | 100 | 145 | 125 | 180 | 135 | 210 |
19 | 100 | 120 | 200 | 210 | 230 | 240 |
20 | 120 | 175 | 120 | 175 | 130 | 185 |
21 | 120 | 100 | 145 | 100 | 145 | 100 |
22 | 150 | 120 | 100 | 155 | No injection (a) | |
23 | 120 | 175 | 165 | 240 | 160 | 235 |
24 | 155 | 140 | 155 | 170 | No injection (c) | |
25 | 145 | 30 | 155 | 30 | 155 | 45 |
26 | 180 | 100 | 210 | 110 | No injection (d) | |
27 | 100 | 120 | 100 | 145 | 100 | 135 |
28 | 115 | 115 | 140 | 140 | 90 | 90 |
29 | 240 | 200 | 165 | 165 | 165 | 165 |
30 | 35 | 20 | 35 | 20 | 35 | 20 |
31 | 60 | 40 | 65 | 85 | 65 | 110 |
Mean | 136.1 | 124.6 | 146.9 | 140.7 | 146.1 | 144.8 |
SD | 54.1 | 61.8 | 48.9 | 62.2 | 57.0 | 73.1 |
Range | 20–100 | 20–120 | 30–90 | 30–80 | 40–100 | 35–100 |
a Other health concerns b Pregnancy c Limited perceived benefit and/or arm muscle weakness d Travel concerns.